To examine if ELAS1 is effective at the bedside, it must be determined if it also causes efficient apoptosis in other cancer cells in which p53-pS46 remains active because many cancer cells show a high incidence of TP53 mutations [16–19]. The gene discussed is TP53; the disease is cancer.